Recent 8-K filings for NEO

• Apr 28, 2026 23:59 UTC earnings materiality 0.78 positive item 2.02item 9.01

  NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M

  Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.

• Feb 17, 2026 23:59 UTC earnings materiality 0.70 neutral item 2.02item 9.01

  NeoGenomics Q4 revenue up 11% to $190M; full-year net loss widens to $108M; RaDaR ST MRD launch imminent

  Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.

• Jan 12, 2026 23:59 UTC other_material materiality 0.70 positive item 2.02item 5.02item 9.01

  NeoGenomics prelim Q4 rev $190M (+11% YoY), FY rev $727M (+10%); CFO Sherman retiring, Jain appointed

  Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).

• Oct 28, 2025 23:59 UTC earnings materiality 0.65 negative item 2.02item 9.01

  NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M

  Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.

• Jul 29, 2025 23:59 UTC earnings materiality 0.75 negative item 2.02item 9.01

  NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance

  Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).

Executive changes

Materiality & sentiment trend

Max materiality 0.78 · Median 0.65 · Most common event earnings

3 positive 2 negative 4 neutral

source · NEO on sec.gov